Live Earnings Conference Call: Inspire Medical Systems will host a live Q1 2025 earnings call on May 5, 2025 at 5:00PM ET. Get details.

Inspire Medical Systems (INSP) Financials

$156.32 -3.49 (-2.18%)

As of 11:35 AM Eastern

Compare

Annual Income Statements for Inspire Medical Systems

This table shows Inspire Medical Systems' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-19	-18	-22	-33	-57	-42	-45	-21	54
Consolidated Net Income / (Loss)	-19	-18	-22	-33	-57	-42	-45	-21	54
Net Income / (Loss) Continuing Operations	-19	-18	-22	-33	-57	-42	-45	-21	54
Total Pre-Tax Income	-19	-18	-22	-33	-57	-42	-44	-20	58
Total Operating Income	-17	-16	-20	-35	-56	-40	-48	-40	36
Total Gross Profit	13	23	41	68	98	200	342	528	680
Total Revenue	16	29	51	82	115	233	408	625	803
Operating Revenue	16	29	51	82	115	233	408	625	803
Total Cost of Revenue	3.91	6.02	10	14	18	33	66	97	123
Total Operating Expenses	30	39	61	103	154	240	389	568	644
Selling, General & Admin Expense	23	32	54	90	128	203	321	452	530
Research & Development Expense	7.09	6.19	7.39	13	26	37	69	117	114
Total Other Income / (Expense), net	-1.28	-1.51	-1.45	1.69	-0.88	-2.12	3.32	20	22
Interest & Investment Income	0.06	0.20	1.87	3.80	1.09	0.13	5.05	21	23
Other Income / (Expense), net	-0.03	0.04	-0.02	0.01	0.15	-0.12	-0.05	-0.20	-0.86
Income Tax Expense	0.00	0.00	0.00	0.04	0.12	0.07	0.61	1.25	4.94
Basic Earnings per Share	($16.90)	($14.88)	($1.50)	($1.40)	($2.19)	($1.54)	($1.60)	($0.72)	$1.80
Weighted Average Basic Shares Outstanding	1.10M	1.18M	14.58M	23.80M	26.07M	27.26M	28.07M	29.30M	29.76M
Diluted Earnings per Share	($16.90)	($14.88)	($1.50)	($1.40)	($2.19)	($1.54)	($1.60)	($0.72)	$1.75
Weighted Average Diluted Shares Outstanding	1.10M	1.18M	14.58M	23.80M	26.07M	27.26M	28.07M	29.30M	30.54M
Weighted Average Basic & Diluted Shares Outstanding	1.10M	1.18M	14.58M	23.80M	26.07M	27.53M	29.05M	29.59M	29.67M

This table shows Inspire Medical Systems' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-17	3.15	-15	-12	-8.54	15	-10	9.79	18	35
Consolidated Net Income / (Loss)	-17	3.15	-15	-12	-8.54	15	-10	9.79	18	35
Net Income / (Loss) Continuing Operations	-17	3.15	-15	-12	-8.54	15	-10	9.79	18	35
Total Pre-Tax Income	-17	3.28	-15	-12	-8.20	15	-9.36	11	20	37
Total Operating Income	-17	-0.34	-19	-17	-13	9.30	-15	5.10	14	32
Total Gross Profit	89	116	108	127	129	164	139	166	171	204
Total Revenue	109	138	128	151	153	193	164	196	203	240
Operating Revenue	109	138	128	151	153	193	164	196	203	240
Total Cost of Revenue	20	22	20	24	24	28	25	30	32	36
Total Operating Expenses	107	116	128	143	142	155	154	161	156	172
Selling, General & Admin Expense	86	95	102	113	113	124	126	132	130	142
Research & Development Expense	21	21	26	31	29	31	29	29	26	30
Total Other Income / (Expense), net	0.59	3.61	4.29	4.86	5.27	5.94	5.86	5.75	6.01	4.75
Interest & Investment Income	1.35	3.37	4.27	4.92	5.50	5.87	5.92	5.88	5.89	5.55
Other Income / (Expense), net	-0.10	0.24	0.02	-0.06	-0.22	0.07	-0.06	-0.14	0.12	-0.78
Income Tax Expense	0.25	0.13	0.22	0.21	0.34	0.48	0.65	1.05	1.83	1.41
Basic Earnings per Share	($0.60)	$0.14	($0.53)	($0.41)	($0.29)	$0.51	($0.34)	$0.33	$0.62	$1.19
Weighted Average Basic Shares Outstanding	28.23M	28.07M	29.09M	29.23M	29.37M	29.30M	29.62M	29.73M	29.88M	29.76M
Diluted Earnings per Share	($0.60)	$0.14	($0.53)	($0.41)	($0.29)	$0.51	($0.34)	$0.32	$0.60	$1.17
Weighted Average Diluted Shares Outstanding	28.23M	28.07M	29.09M	29.23M	29.37M	29.30M	29.62M	30.41M	30.63M	30.54M
Weighted Average Basic & Diluted Shares Outstanding	28.89M	29.05M	29.17M	29.34M	29.52M	29.59M	29.71M	29.82M	29.97M	29.67M

This table details how cash moves in and out of Inspire Medical Systems' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-5.44	2.27	88	-74	168	24	227	-256	-35
Net Cash From Operating Activities	-18	-16	-19	-33	-53	-20	12	25	130
Net Cash From Continuing Operating Activities	-18	-16	-19	-33	-53	-20	12	25	130
Net Income / (Loss) Continuing Operations	-19	-18	-22	-33	-57	-42	-45	-21	54
Consolidated Net Income / (Loss)	-19	-18	-22	-33	-57	-42	-45	-21	54
Depreciation Expense	0.10	0.29	0.39	0.50	0.84	1.22	1.86	2.85	6.55
Amortization Expense	0.18	0.32	-0.08	-0.72	-	0.01	-0.00	-2.47	-8.86
Non-Cash Adjustments To Reconcile Net Income	0.05	0.34	1.96	7.19	14	28	53	86	117
Changes in Operating Assets and Liabilities, net	0.24	0.78	0.86	-6.57	-11	-6.86	1.81	-41	-38
Net Cash From Investing Activities	-0.31	-7.60	-83	-44	87	29	-20	-295	-113
Net Cash From Continuing Investing Activities	-0.31	-7.60	-83	-44	87	29	-20	-295	-113
Purchase of Property, Plant & Equipment	-0.31	-0.41	-0.25	-2.74	-2.46	-4.67	-9.10	-24	-39
Purchase of Investments	0.00	-8.97	-115	-178	-53	-9.99	-11	-281	-419
Sale and/or Maturity of Investments	0.00	1.78	32	137	142	44	0.00	10	345
Net Cash From Financing Activities	13	26	190	1.96	134	15	235	14	-52
Net Cash From Continuing Financing Activities	13	26	190	1.96	134	15	235	14	-52
Repayment of Debt	-	0.00	0.00	-0.53	0.00	0.00	-25	0.00	0.00
Repurchase of Common Equity	-	-	-	-	-	-	0.00	0.00	-75
Issuance of Common Equity	0.00	0.00	182	1.36	127	3.47	248	5.30	5.61
Other Financing Activities, net	0.47	0.24	0.56	1.14	7.05	11	12	8.65	17
Effect of Exchange Rate Changes	0.00	0.00	0.03	0.01	0.01	-0.02	0.08	0.16	-0.12
Cash Interest Paid	1.23	1.32	2.02	2.03	1.89	1.89	2.32	0.00	0.02

This table details how cash moves in and out of Inspire Medical Systems' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	231	24	0.54	25	-137	-144	-10	13	-41	2.64
Net Cash From Operating Activities	11	19	-1.34	5.09	3.64	17	8.86	-0.08	52	69
Net Cash From Continuing Operating Activities	11	19	-1.34	5.09	3.64	17	8.86	-0.08	52	69
Net Income / (Loss) Continuing Operations	-17	3.15	-15	-12	-8.54	15	-10	9.79	18	35
Consolidated Net Income / (Loss)	-17	3.15	-15	-12	-8.54	15	-10	9.79	18	35
Depreciation Expense	0.51	0.57	0.59	0.66	0.78	0.82	0.84	1.38	1.85	2.48
Amortization Expense	-	-	-0.00	-	-0.07	-2.40	-2.47	-2.44	-2.41	-1.54
Non-Cash Adjustments To Reconcile Net Income	14	15	19	23	21	24	25	33	29	30
Changes in Operating Assets and Liabilities, net	13	0.20	-5.09	-6.48	-9.30	-20	-4.95	-42	5.68	3.11
Net Cash From Investing Activities	-3.76	-2.95	-3.75	4.90	-144	-152	-20	5.62	-103	3.76
Net Cash From Continuing Investing Activities	-3.76	-2.95	-3.75	4.90	-144	-152	-20	5.62	-103	3.76
Purchase of Property, Plant & Equipment	-3.51	-2.95	-3.75	-4.86	-6.99	-8.03	-12	-12	-8.01	-7.03
Purchase of Investments	-0.25	-	0.00	-0.25	-137	-144	-56	-56	-226	-81
Sale and/or Maturity of Investments	-	-	0.00	10	-	0.25	48	74	131	92
Net Cash From Financing Activities	224	7.29	5.63	15	3.50	-10	0.77	7.09	9.89	-70
Net Cash From Continuing Financing Activities	224	7.29	5.63	15	3.50	-10	0.77	7.09	9.89	-70
Issuance of Common Equity	244	1.60	-	-	-	2.51	-	-	-	2.17
Other Financing Activities, net	1.76	5.69	5.63	12	3.50	-13	0.77	3.66	9.89	2.69
Effect of Exchange Rate Changes	-0.13	0.18	0.01	-0.00	-0.05	0.21	-0.21	-0.01	0.27	-0.17

This table presents Inspire Medical Systems' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	25	200	181	281	295	565	677	808
Total Current Assets	24	199	171	270	269	530	594	631
Cash & Equivalents	8.96	97	23	191	214	442	186	150
Short-Term Investments	7.19	91	127	44	0.00	9.82	275	295
Accounts Receivable	3.86	6.67	13	25	34	61	90	93
Inventories, net	3.67	2.67	5.83	8.48	17	12	34	80
Prepaid Expenses	0.43	1.73	2.21	1.97	2.66	5.51	9.60	12
Plant, Property, & Equipment, net	0.99	0.80	3.05	5.31	8.49	17	40	72
Total Noncurrent Assets	0.00	0.00	7.57	6.01	18	18	43	106
Long-Term Investments	-	0.00	6.28	0.00	9.94	0.00	9.14	71
Other Noncurrent Operating Assets	-	0.00	1.30	6.01	8.12	18	34	35
Total Liabilities & Shareholders' Equity	25	200	181	281	295	565	677	808
Total Liabilities	24	36	41	51	66	69	104	119
Total Current Liabilities	7.15	11	17	21	41	61	78	89
Accounts Payable	3.00	3.43	4.46	7.21	12	27	39	39
Accrued Expenses	4.15	7.73	12	14	20	34	39	50
Total Noncurrent Liabilities	17	25	25	31	25	7.68	26	30
Other Noncurrent Operating Liabilities	0.16	0.00	0.04	5.97	8.93	7.68	26	30
Commitments & Contingencies	-	-	-	-	-	-	0.00	0.00
Total Equity & Noncontrolling Interests	1.33	164	140	230	229	496	573	690
Total Preferred & Common Equity	1.33	164	140	230	229	496	573	690
Preferred Stock	119	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-118	164	140	230	229	496	573	690
Common Stock	7.31	311	320	467	508	820	917	981
Retained Earnings	-125	-147	-180	-237	-279	-324	-345	-292
Accumulated Other Comprehensive Income / (Loss)	0.00	-0.05	0.10	0.03	-0.06	-0.09	0.80	0.54

This table presents Inspire Medical Systems' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	528	572	618	639	686	728	796
Total Current Assets	496	534	560	570	572	607	583
Cash & Equivalents	418	442	467	330	175	188	148
Short-Term Investments	9.74	9.93	0.00	134	266	252	263
Accounts Receivable	48	60	64	71	72	80	90
Inventories, net	15	16	21	26	49	59	67
Prepaid Expenses	4.35	6.09	8.69	7.80	9.55	29	14
Plant, Property, & Equipment, net	14	21	25	32	52	62	67
Total Noncurrent Assets	18	17	33	38	61	60	146
Long-Term Investments	0.00	-	-	2.96	28	26	113
Other Noncurrent Operating Assets	18	17	33	35	34	33	33
Total Liabilities & Shareholders' Equity	528	572	618	639	686	728	796
Total Liabilities	57	67	89	95	97	90	100
Total Current Liabilities	49	60	67	70	72	66	74
Accounts Payable	20	36	40	40	44	34	35
Accrued Expenses	29	23	27	30	28	32	39
Total Noncurrent Liabilities	8.03	7.33	22	25	25	25	25
Other Noncurrent Operating Liabilities	8.03	7.33	22	25	25	25	25
Total Equity & Noncontrolling Interests	470	505	529	544	589	638	697
Total Preferred & Common Equity	470	505	529	544	589	638	697
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	470	505	529	544	589	638	697
Common Stock	798	844	881	904	944	984	1,022
Retained Earnings	-327	-340	-352	-360	-355	-346	-327
Accumulated Other Comprehensive Income / (Loss)	-0.36	0.03	0.10	0.04	0.12	-0.12	1.70

This table displays calculated financial ratios and metrics derived from Inspire Medical Systems' official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	73.90%	77.10%	62.18%	40.62%	102.28%	74.75%	53.19%	28.49%
EBITDA Growth	0.00%	9.64%	-30.73%	-74.82%	-57.31%	29.86%	-18.21%	12.44%	182.11%
EBIT Growth	0.00%	7.64%	-27.77%	-71.06%	-60.71%	28.71%	-19.20%	15.06%	187.06%
NOPAT Growth	0.00%	7.25%	-27.34%	-71.25%	-61.07%	29.10%	-19.43%	15.38%	217.17%
Net Income Growth	0.00%	5.49%	-24.65%	-52.30%	-72.08%	26.50%	-6.75%	52.87%	352.96%
EPS Growth	0.00%	11.95%	89.92%	6.67%	-56.43%	29.68%	-3.90%	55.00%	343.06%
Operating Cash Flow Growth	0.00%	12.02%	-18.38%	-75.70%	-61.50%	62.07%	157.50%	113.10%	428.32%
Free Cash Flow Firm Growth	0.00%	0.00%	-3.81%	-142.43%	-57.32%	26.48%	-29.11%	-79.35%	57.12%
Invested Capital Growth	0.00%	0.00%	-56.51%	1,105.04%	133.65%	47.19%	50.51%	130.96%	68.12%
Revenue Q/Q Growth	0.00%	0.00%	15.01%	14.43%	19.84%	16.11%	17.08%	9.58%	6.25%
EBITDA Q/Q Growth	0.00%	0.00%	-9.43%	-12.41%	4.11%	11.95%	4.14%	15.30%	279.95%
EBIT Q/Q Growth	0.00%	0.00%	-5.72%	-14.34%	3.92%	11.42%	3.55%	18.95%	161.10%
NOPAT Q/Q Growth	0.00%	0.00%	-5.44%	-14.41%	3.82%	11.62%	3.03%	19.30%	174.44%
Net Income Q/Q Growth	0.00%	0.00%	-2.47%	-14.86%	2.71%	10.81%	10.99%	35.44%	61.91%
EPS Q/Q Growth	0.00%	0.00%	83.55%	-143.89%	6.01%	9.94%	12.09%	33.95%	60.55%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	3.55%	-11.88%	3.57%	19.40%	266.08%	-7.51%	66.27%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-18.07%	-0.74%	1.88%	7.10%	-24.98%	55.33%
Invested Capital Q/Q Growth	0.00%	0.00%	-75.20%	-3.34%	8.85%	18.33%	4.55%	33.75%	0.58%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	76.23%	78.93%	80.12%	83.37%	84.73%	85.74%	83.79%	84.54%	84.68%
EBITDA Margin	-103.48%	-53.77%	-39.69%	-42.78%	-47.86%	-16.60%	-11.23%	-6.42%	4.10%
Operating Margin	-105.03%	-56.02%	-40.28%	-42.53%	-48.72%	-17.07%	-11.67%	-6.45%	4.49%
EBIT Margin	-105.20%	-55.87%	-40.31%	-42.52%	-48.59%	-17.12%	-11.68%	-6.48%	4.39%
Profit (Net Income) Margin	-112.79%	-61.30%	-43.14%	-40.52%	-49.58%	-18.01%	-11.00%	-3.39%	6.67%
Tax Burden Percent	100.00%	100.00%	100.00%	100.12%	100.20%	100.17%	101.38%	106.26%	91.54%
Interest Burden Percent	107.21%	109.71%	107.03%	95.18%	101.83%	105.01%	92.92%	49.19%	165.93%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8.46%
Return on Invested Capital (ROIC)	0.00%	-1,362.79%	-1,209.38%	-523.59%	-273.74%	-112.12%	-89.77%	-38.20%	23.92%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-5,343.16%	-1,200.09%	-517.60%	-263.26%	-105.20%	-86.21%	-39.73%	19.77%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-1,276.40%	1,182.97%	501.70%	242.78%	93.79%	77.39%	34.24%	-15.44%
Return on Equity (ROE)	0.00%	-2,639.19%	-26.41%	-21.88%	-30.96%	-18.33%	-12.38%	-3.96%	8.48%
Cash Return on Invested Capital (CROIC)	0.00%	-1,562.79%	-1,130.61%	-692.94%	-353.85%	-150.29%	-130.09%	-117.34%	-26.89%
Operating Return on Assets (OROA)	0.00%	-63.61%	-18.11%	-18.30%	-24.25%	-13.87%	-11.08%	-6.52%	4.74%
Return on Assets (ROA)	0.00%	-69.79%	-19.39%	-17.44%	-24.74%	-14.59%	-10.44%	-3.41%	7.21%
Return on Common Equity (ROCE)	0.00%	234,243.18%	-7.38%	-21.88%	-30.96%	-18.33%	-12.38%	-3.96%	8.48%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-1,319.59%	-13.31%	-23.77%	-24.90%	-18.36%	-9.05%	-3.69%	7.76%
Net Operating Profit after Tax (NOPAT)	-12	-11	-14	-24	-39	-28	-33	-28	33
NOPAT Margin	-73.52%	-39.21%	-28.19%	-29.77%	-34.10%	-11.95%	-8.17%	-4.51%	4.11%
Net Nonoperating Expense Percent (NNEP)	0.00%	3,980.38%	-9.28%	-5.99%	-10.48%	-6.92%	-3.55%	1.53%	4.15%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-6.72%	-4.92%	4.79%
Cost of Revenue to Revenue	23.77%	21.07%	19.88%	16.63%	15.27%	14.26%	16.21%	15.46%	15.32%
SG&A Expenses to Revenue	138.09%	113.27%	105.80%	110.26%	110.83%	86.81%	78.63%	72.34%	65.97%
R&D to Revenue	43.17%	21.68%	14.60%	15.65%	22.61%	16.00%	16.83%	18.65%	14.22%
Operating Expenses to Revenue	181.26%	134.95%	120.40%	125.90%	133.44%	102.82%	95.46%	90.99%	80.19%
Earnings before Interest and Taxes (EBIT)	-17	-16	-20	-35	-56	-40	-48	-40	35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-17	-15	-20	-35	-55	-39	-46	-40	33
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	5.51	12.77	22.05	27.48	14.67	10.49	8.05
Price to Tangible Book Value (P/TBV)	0.00	0.00	5.51	12.77	22.05	27.48	14.67	10.49	8.05
Price to Revenue (P/Rev)	6.57	3.78	17.87	21.76	43.91	26.97	17.84	9.61	6.92
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	103.82
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.96%
Enterprise Value to Invested Capital (EV/IC)	0.00	138.34	1,036.20	192.02	241.25	205.69	153.07	53.76	29.10
Enterprise Value to Revenue (EV/Rev)	0.00	7.96	14.64	20.16	42.09	26.11	16.74	8.86	6.28
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	153.06
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	143.03
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	152.55
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	590.03	224.58	38.69
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	12.40	0.15	0.18	0.11	0.11	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	12.40	0.15	0.18	0.11	0.07	0.00	0.00	0.00
Financial Leverage	0.00	0.24	-0.99	-0.97	-0.92	-0.89	-0.90	-0.86	-0.78
Leverage Ratio	0.00	18.91	1.36	1.26	1.25	1.26	1.19	1.16	1.18
Compound Leverage Factor	0.00	20.74	1.46	1.19	1.27	1.32	1.10	0.57	1.95
Debt to Total Capital	0.00%	92.54%	13.19%	14.92%	9.72%	9.84%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	3.62%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	92.54%	13.19%	14.92%	9.72%	6.22%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	669.62%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-662.16%	86.81%	85.08%	90.28%	90.16%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	-1.07	-1.24	-0.70	-0.45	-0.65	0.00	0.00	0.00
Net Debt to EBITDA	0.00	-0.02	8.13	3.74	3.80	5.15	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	-1.07	-1.24	-0.70	-0.45	-0.41	0.00	0.00	0.00
Debt to NOPAT	0.00	-1.47	-1.75	-1.00	-0.63	-0.90	0.00	0.00	0.00
Net Debt to NOPAT	0.00	-0.03	11.45	5.37	5.33	7.15	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	-1.47	-1.75	-1.00	-0.63	-0.57	0.00	0.00	0.00
Altman Z-Score	0.00	-4.40	15.05	25.31	58.72	57.13	64.04	35.48	29.52
Noncontrolling Interest Sharing Ratio	0.00%	8,975.58%	72.04%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	3.37	17.86	10.12	13.02	6.50	8.66	7.60	7.13
Quick Ratio	0.00	2.80	17.47	9.65	12.52	6.02	8.38	7.05	6.09
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-13	-13	-32	-51	-37	-48	-87	-37
Operating Cash Flow to CapEx	-5,865.69%	-3,832.77%	-7,477.60%	-1,199.20%	-2,160.69%	-431.00%	127.19%	104.33%	332.91%
Free Cash Flow to Firm to Interest Expense	0.00	-7.33	-4.04	-15.26	-24.02	-17.57	-28.79	0.00	0.00
Operating Cash Flow to Interest Expense	-13.78	-9.01	-5.66	-15.50	-25.06	-9.45	6.90	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-14.01	-9.24	-5.73	-16.79	-26.22	-11.65	1.47	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	1.14	0.45	0.43	0.50	0.81	0.95	1.01	1.08
Accounts Receivable Turnover	0.00	7.40	9.61	8.29	6.04	7.88	8.55	8.27	8.78
Inventory Turnover	0.00	1.64	3.17	3.21	2.46	2.59	4.54	4.22	2.16
Fixed Asset Turnover	0.00	28.74	56.34	42.66	27.62	33.83	31.70	21.83	14.35
Accounts Payable Turnover	0.00	2.01	3.13	3.46	3.02	3.53	3.43	2.94	3.17
Days Sales Outstanding (DSO)	0.00	49.29	37.97	44.04	60.41	46.32	42.69	44.14	41.59
Days Inventory Outstanding (DIO)	0.00	222.59	115.01	113.72	148.22	140.99	80.37	86.49	169.17
Days Payable Outstanding (DPO)	0.00	181.83	116.64	105.52	120.83	103.50	106.31	124.13	115.04
Cash Conversion Cycle (CCC)	0.00	90.05	36.33	52.24	87.80	83.81	16.76	6.51	95.72
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	1.64	0.72	8.62	20	30	45	103	173
Invested Capital Turnover	0.00	34.75	42.89	17.59	8.03	9.38	10.99	8.47	5.81
Increase / (Decrease) in Invested Capital	0.00	1.64	-0.93	7.90	12	9.50	15	58	70
Enterprise Value (EV)	0.00	227	741	1,654	4,857	6,095	6,826	5,537	5,039
Market Capitalization	108	108	904	1,786	5,066	6,294	7,277	6,006	5,555
Book Value per Share	$0.00	($100.10)	$7.66	$5.81	$8.53	$8.37	$17.17	$19.39	$23.02
Tangible Book Value per Share	$0.00	($100.10)	$7.66	$5.81	$8.53	$8.37	$17.17	$19.39	$23.02
Total Capital	0.00	18	189	164	254	254	496	573	690
Total Debt	0.00	16	25	25	25	25	0.00	0.00	0.00
Total Long-Term Debt	0.00	16	25	25	25	16	0.00	0.00	0.00
Net Debt	0.00	0.32	-163	-131	-210	-199	-451	-470	-517
Capital Expenditures (CapEx)	0.31	0.41	0.25	2.74	2.46	4.67	9.10	24	39
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	0.81	-0.09	4.32	15	22	17	55	97
Debt-free Net Working Capital (DFNWC)	0.00	17	188	154	249	236	469	516	542
Net Working Capital (NWC)	0.00	17	188	154	249	227	469	516	542
Net Nonoperating Expense (NNE)	6.45	6.31	7.56	8.82	18	14	12	-7.04	-20
Net Nonoperating Obligations (NNO)	0.00	0.32	-163	-131	-210	-199	-451	-470	-517
Total Depreciation and Amortization (D&A)	0.28	0.60	0.31	-0.22	0.84	1.23	1.85	0.38	-2.31
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	2.82%	-0.17%	5.26%	12.81%	9.41%	4.27%	8.84%	12.05%
Debt-free Net Working Capital to Revenue	0.00%	59.33%	371.84%	187.42%	215.93%	101.30%	114.95%	82.53%	67.55%
Net Working Capital to Revenue	0.00%	59.33%	371.84%	187.42%	215.93%	97.36%	114.95%	82.53%	67.55%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($1.50)	($1.40)	($2.19)	($1.54)	($1.60)	($0.72)	$1.80
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	23.44M	24.13M	27.13M	27.26M	28.07M	29.30M	29.76M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($1.50)	($1.40)	($2.19)	($1.54)	($1.60)	($0.72)	$1.75
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	23.44M	24.13M	27.13M	27.26M	28.07M	29.30M	30.54M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($1.50)	($1.40)	($2.19)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	14.58M	23.80M	26.07M	27.53M	29.05M	29.59M	29.67M
Normalized Net Operating Profit after Tax (NOPAT)	-12	-11	-14	-24	-39	-28	-33	-28	33
Normalized NOPAT Margin	-73.52%	-39.21%	-28.19%	-29.77%	-34.10%	-11.95%	-8.17%	-4.51%	4.11%
Pre Tax Income Margin	-112.79%	-61.30%	-43.14%	-40.47%	-49.48%	-17.98%	-10.85%	-3.19%	7.28%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-13.26	-9.11	-6.17	-16.46	-26.48	-18.78	-28.41	0.00	0.00
NOPAT to Interest Expense	-9.27	-6.39	-4.32	-11.53	-18.59	-13.11	-19.87	0.00	0.00
EBIT Less CapEx to Interest Expense	-13.50	-9.34	-6.25	-17.76	-27.64	-20.98	-33.83	0.00	0.00
NOPAT Less CapEx to Interest Expense	-9.50	-6.63	-4.39	-12.82	-19.75	-15.30	-25.29	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	140.16%

This table displays calculated financial ratios and metrics derived from Inspire Medical Systems' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	77.01%	75.90%	84.34%	65.33%	40.40%	39.60%	28.24%	29.65%	32.54%	24.52%
EBITDA Growth	-76.78%	131.58%	-19.99%	-16.51%	22.62%	1,539.37%	10.49%	124.43%	206.85%	311.48%
EBIT Growth	-75.96%	94.91%	-20.99%	-17.73%	20.82%	10,068.09%	21.57%	129.80%	205.41%	231.97%
NOPAT Growth	-75.52%	74.72%	-21.44%	-18.51%	21.65%	2,895.04%	21.95%	139.62%	238.18%	240.39%
Net Income Growth	-62.82%	231.74%	7.61%	17.52%	49.31%	368.67%	35.13%	181.94%	316.59%	138.60%
EPS Growth	-57.89%	275.00%	13.11%	22.64%	51.67%	264.29%	35.85%	178.05%	306.90%	129.41%
Operating Cash Flow Growth	3,355.03%	2,525.20%	89.46%	185.52%	-66.93%	-10.39%	759.23%	-101.53%	1,337.14%	300.65%
Free Cash Flow Firm Growth	-121.22%	-41.89%	-9.57%	40.31%	-47.65%	-223.11%	-166.66%	-395.52%	-87.57%	20.03%
Invested Capital Growth	70.35%	50.51%	42.07%	18.22%	80.53%	130.96%	127.92%	176.15%	123.56%	68.12%
Revenue Q/Q Growth	19.48%	26.30%	-7.25%	18.14%	1.46%	25.57%	-14.80%	19.43%	3.73%	17.98%
EBITDA Q/Q Growth	-22.19%	102.83%	-4,076.63%	15.29%	18.84%	159.96%	-265.98%	123.12%	254.98%	130.92%
EBIT Q/Q Growth	-22.22%	99.46%	-20,624.47%	14.48%	17.80%	168.42%	-263.05%	132.49%	190.81%	115.48%
NOPAT Q/Q Growth	-22.75%	97.32%	-4,135.88%	14.87%	18.84%	195.51%	-218.28%	143.22%	183.01%	135.27%
Net Income Q/Q Growth	-16.27%	118.70%	-589.65%	22.51%	28.55%	272.87%	-167.77%	197.88%	88.88%	90.43%
EPS Q/Q Growth	-13.21%	123.33%	-478.57%	22.64%	29.27%	275.86%	-166.67%	194.12%	87.50%	95.00%
Operating Cash Flow Q/Q Growth	284.78%	75.14%	-106.97%	478.87%	-28.55%	374.63%	-48.69%	-100.88%	67,129.49%	32.32%
Free Cash Flow Firm Q/Q Growth	16.59%	48.44%	-91.15%	27.38%	-106.31%	-12.83%	-57.76%	-34.94%	21.91%	51.89%
Invested Capital Q/Q Growth	-19.07%	4.55%	17.93%	18.48%	23.59%	33.75%	16.37%	43.55%	0.05%	0.58%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	81.88%	83.94%	84.45%	83.95%	84.10%	85.43%	84.91%	84.77%	84.06%	84.99%
EBITDA Margin	-15.37%	0.34%	-14.77%	-10.59%	-8.47%	4.05%	-10.31%	2.00%	6.83%	13.37%
Operating Margin	-15.75%	-0.24%	-15.25%	-10.99%	-8.79%	4.83%	-9.28%	2.60%	7.05%	13.30%
EBIT Margin	-15.84%	-0.07%	-15.23%	-11.03%	-8.93%	4.87%	-9.32%	2.53%	7.10%	12.98%
Profit (Net Income) Margin	-15.43%	2.28%	-12.06%	-7.91%	-5.57%	7.67%	-6.10%	5.00%	9.10%	14.69%
Tax Burden Percent	101.48%	96.18%	101.42%	101.82%	104.15%	96.87%	106.95%	90.29%	91.00%	96.15%
Interest Burden Percent	95.99%	-3,484.04%	78.07%	70.46%	59.88%	162.65%	61.23%	218.49%	140.80%	117.78%
Effective Tax Rate	0.00%	3.82%	0.00%	0.00%	0.00%	3.13%	0.00%	9.71%	9.00%	3.85%
Return on Invested Capital (ROIC)	-113.45%	-2.57%	-111.09%	-70.35%	-58.62%	39.61%	-49.79%	14.15%	38.89%	74.35%
ROIC Less NNEP Spread (ROIC-NNEP)	-111.90%	-3.63%	-110.53%	-70.25%	-58.82%	38.36%	-49.93%	13.04%	37.79%	73.43%
Return on Net Nonoperating Assets (RNNOA)	100.93%	3.26%	96.96%	59.56%	51.88%	-33.06%	42.05%	-10.42%	-30.20%	-57.36%
Return on Equity (ROE)	-12.52%	0.69%	-14.13%	-10.79%	-6.74%	6.55%	-7.73%	3.73%	8.69%	16.99%
Cash Return on Invested Capital (CROIC)	-153.54%	-130.09%	-114.50%	-81.97%	-115.80%	-117.34%	-107.24%	-102.25%	-66.71%	-26.89%
Operating Return on Assets (OROA)	-13.68%	-0.06%	-16.49%	-12.75%	-8.73%	4.90%	-9.79%	2.66%	7.48%	14.03%
Return on Assets (ROA)	-13.33%	2.17%	-13.06%	-9.14%	-5.44%	7.72%	-6.41%	5.24%	9.58%	15.89%
Return on Common Equity (ROCE)	-12.52%	0.69%	-14.13%	-10.79%	-6.74%	6.55%	-7.73%	3.73%	8.69%	16.99%
Return on Equity Simple (ROE_SIMPLE)	-10.72%	0.00%	-8.64%	-7.76%	-6.02%	0.00%	-2.67%	0.94%	4.74%	0.00%
Net Operating Profit after Tax (NOPAT)	-12	-0.32	-14	-12	-9.43	9.01	-11	4.60	13	31
NOPAT Margin	-11.02%	-0.23%	-10.67%	-7.69%	-6.15%	4.68%	-6.50%	2.35%	6.41%	12.79%
Net Nonoperating Expense Percent (NNEP)	-1.55%	1.07%	-0.55%	-0.10%	0.20%	1.25%	0.14%	1.11%	1.10%	0.93%
Return On Investment Capital (ROIC_SIMPLE)	-	-0.07%	-	-	-	1.57%	-	-	-	4.44%
Cost of Revenue to Revenue	18.12%	16.06%	15.55%	16.05%	15.90%	14.57%	15.09%	15.24%	15.94%	15.01%
SG&A Expenses to Revenue	78.40%	68.77%	79.74%	74.54%	73.87%	64.47%	76.59%	67.43%	64.17%	59.03%
R&D to Revenue	19.23%	15.41%	19.95%	20.40%	19.01%	16.13%	17.59%	14.73%	12.84%	12.65%
Operating Expenses to Revenue	97.63%	84.18%	99.70%	94.93%	92.88%	80.60%	94.18%	82.16%	77.01%	71.69%
Earnings before Interest and Taxes (EBIT)	-17	-0.09	-19	-17	-14	9.37	-15	4.96	14	31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-17	0.48	-19	-16	-13	7.79	-17	3.91	14	32
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	10.43	14.67	13.47	17.89	10.70	10.49	10.77	6.23	9.04	8.05
Price to Tangible Book Value (P/TBV)	10.43	14.67	13.47	17.89	10.70	10.49	10.77	6.23	9.04	8.05
Price to Revenue (P/Rev)	14.07	17.84	14.58	18.00	10.21	9.61	9.60	5.63	8.33	6.92
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	661.49	190.45	103.82
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.15%	0.53%	0.96%
Enterprise Value to Invested Capital (EV/IC)	104.90	153.07	120.70	144.50	69.53	53.76	48.99	20.40	33.51	29.10
Enterprise Value to Revenue (EV/Rev)	12.85	16.74	13.61	17.11	9.39	8.86	8.89	4.97	7.64	6.28
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	665.91	153.06
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	427.62	143.03
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	479.35	152.55
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	590.03	276.29	264.66	200.87	224.58	168.47	118.24	73.65	38.69
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.90	-0.90	-0.88	-0.85	-0.88	-0.86	-0.84	-0.80	-0.80	-0.78
Leverage Ratio	1.17	1.19	1.18	1.20	1.15	1.16	1.15	1.15	1.16	1.18
Compound Leverage Factor	1.12	-41.32	0.92	0.85	0.69	1.89	0.70	2.52	1.63	1.39
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	52.01	64.32	61.58	64.85	37.62	35.72	40.34	27.63	39.10	29.50
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.05	8.66	8.91	8.40	8.14	7.60	7.93	9.25	7.84	7.13
Quick Ratio	9.66	8.38	8.55	7.96	7.65	7.05	7.12	7.91	6.74	6.09
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-30	-15	-29	-21	-44	-49	-78	-105	-82	-40
Operating Cash Flow to CapEx	313.27%	653.19%	-35.81%	104.88%	52.06%	214.95%	75.75%	-0.63%	652.97%	984.50%
Free Cash Flow to Firm to Interest Expense	-45.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	16.77	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	11.42	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.86	0.95	1.08	1.16	0.98	1.01	1.05	1.05	1.05	1.08
Accounts Receivable Turnover	9.27	8.55	9.89	10.13	9.51	8.27	10.01	9.86	9.37	8.78
Inventory Turnover	3.59	4.54	4.01	4.03	4.40	4.22	3.14	2.68	2.46	2.16
Fixed Asset Turnover	31.60	31.70	30.83	29.04	24.59	21.83	18.06	16.24	15.16	14.35
Accounts Payable Turnover	3.64	3.43	2.84	3.07	3.01	2.94	2.53	2.91	3.07	3.17
Days Sales Outstanding (DSO)	39.38	42.69	36.91	36.04	38.39	44.14	36.48	37.04	38.94	41.59
Days Inventory Outstanding (DIO)	101.71	80.37	90.92	90.52	83.05	86.49	116.28	136.17	148.39	169.17
Days Payable Outstanding (DPO)	100.30	106.31	128.47	118.72	121.44	124.13	144.42	125.46	118.90	115.04
Cash Conversion Cycle (CCC)	40.79	16.76	-0.65	7.84	0.00	6.51	8.34	47.75	68.42	95.72
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	43	45	53	62	77	103	120	172	172	173
Invested Capital Turnover	10.29	10.99	10.41	9.15	9.53	8.47	7.67	6.02	6.07	5.81
Increase / (Decrease) in Invested Capital	18	15	16	9.60	34	58	67	110	95	70
Enterprise Value (EV)	4,475	6,826	6,347	9,003	5,354	5,537	5,872	3,510	5,769	5,039
Market Capitalization	4,902	7,277	6,799	9,470	5,821	6,006	6,342	3,976	6,294	5,555
Book Value per Share	$17.01	$17.17	$17.37	$18.15	$18.55	$19.39	$19.89	$21.48	$23.36	$23.02
Tangible Book Value per Share	$17.01	$17.17	$17.37	$18.15	$18.55	$19.39	$19.89	$21.48	$23.36	$23.02
Total Capital	470	496	505	529	544	573	589	638	697	690
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-428	-451	-452	-467	-467	-470	-469	-466	-524	-517
Capital Expenditures (CapEx)	3.51	2.95	3.75	4.86	6.99	8.03	12	12	8.01	7.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	19	17	22	26	35	55	59	102	97	97
Debt-free Net Working Capital (DFNWC)	446	469	474	493	500	516	500	542	508	542
Net Working Capital (NWC)	446	469	474	493	500	516	500	542	508	542
Net Nonoperating Expense (NNE)	4.81	-3.47	1.78	0.33	-0.89	-5.76	-0.65	-5.19	-5.47	-4.57
Net Nonoperating Obligations (NNO)	-428	-451	-452	-467	-467	-470	-469	-466	-524	-517
Total Depreciation and Amortization (D&A)	0.51	0.57	0.59	0.66	0.71	-1.58	-1.63	-1.06	-0.56	0.94
Debt-free, Cash-free Net Working Capital to Revenue	5.37%	4.27%	4.64%	5.01%	6.21%	8.84%	8.88%	14.43%	12.87%	12.05%
Debt-free Net Working Capital to Revenue	128.10%	114.95%	101.57%	93.79%	87.62%	82.53%	75.66%	76.73%	67.27%	67.55%
Net Working Capital to Revenue	128.10%	114.95%	101.57%	93.79%	87.62%	82.53%	75.66%	76.73%	67.27%	67.55%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.60)	$0.14	($0.53)	($0.41)	($0.29)	$0.51	($0.34)	$0.33	$0.62	$1.19
Adjusted Weighted Average Basic Shares Outstanding	28.23M	28.07M	29.09M	29.23M	29.37M	29.30M	29.62M	29.73M	29.88M	29.76M
Adjusted Diluted Earnings per Share	($0.60)	$0.14	($0.53)	($0.41)	($0.29)	$0.51	($0.34)	$0.32	$0.60	$1.17
Adjusted Weighted Average Diluted Shares Outstanding	28.23M	28.07M	29.09M	29.23M	29.37M	29.30M	29.62M	30.41M	30.63M	30.54M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	28.89M	29.05M	29.17M	29.34M	29.52M	29.59M	29.71M	29.82M	29.97M	29.67M
Normalized Net Operating Profit after Tax (NOPAT)	-12	-0.32	-14	-12	-9.43	9.01	-11	4.60	13	31
Normalized NOPAT Margin	-11.02%	-0.23%	-10.67%	-7.69%	-6.15%	4.68%	-6.50%	2.35%	6.41%	12.79%
Pre Tax Income Margin	-15.20%	2.37%	-11.89%	-7.77%	-5.35%	7.92%	-5.70%	5.54%	10.00%	15.28%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-26.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-18.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-31.72	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-23.70	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	140.16%

Frequently Asked Questions About Inspire Medical Systems' Financials

When does Inspire Medical Systems's fiscal year end?

According to the most recent income statement we have on file, Inspire Medical Systems' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Inspire Medical Systems' net income changed over the last 8 years?

Inspire Medical Systems' net income appears to be on a downward trend, with a most recent value of $53.51 million in 2024, falling from -$18.53 million in 2016. The previous period was -$21.15 million in 2023. Find out what analysts predict for Inspire Medical Systems in the coming months.

What is Inspire Medical Systems's operating income?

Inspire Medical Systems's total operating income in 2024 was $36.08 million, based on the following breakdown:

Total Gross Profit: $679.82 million
Total Operating Expenses: $643.74 million

How has Inspire Medical Systems revenue changed over the last 8 years?

Over the last 8 years, Inspire Medical Systems' total revenue changed from $16.43 million in 2016 to $802.80 million in 2024, a change of 4,787.1%.

How much debt does Inspire Medical Systems have?

Inspire Medical Systems' total liabilities were at $118.69 million at the end of 2024, a 13.8% increase from 2023, and a 399.4% increase since 2017.

How much cash does Inspire Medical Systems have?

In the past 7 years, Inspire Medical Systems' cash and equivalents has ranged from $8.96 million in 2017 to $441.59 million in 2022, and is currently $150.15 million as of their latest financial filing in 2024.

How has Inspire Medical Systems' book value per share changed over the last 8 years?

Over the last 8 years, Inspire Medical Systems' book value per share changed from 0.00 in 2016 to 23.02 in 2024, a change of 2,301.5%.

Related Companies

This page (NYSE:INSP) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inspire Medical Systems (INSP) Financials

Frequently Asked Questions About Inspire Medical Systems' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inspire Medical Systems (INSP) Financials

Annual Income Statements for Inspire Medical Systems

Quarterly Income Statements for Inspire Medical Systems

Annual Cash Flow Statements for Inspire Medical Systems

Quarterly Cash Flow Statements for Inspire Medical Systems

Annual Balance Sheets for Inspire Medical Systems

Quarterly Balance Sheets for Inspire Medical Systems

Annual Metrics and Ratios for Inspire Medical Systems

Quarterly Metrics and Ratios for Inspire Medical Systems

Frequently Asked Questions About Inspire Medical Systems' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools